In Vitro mRNA Synthesis CDMO Services

In Vitro mRNA Synthesis CDMO — Elise Biopharma

Plasmid-to-LNP Continuum │ Digital QC │ GMP Lot Release

Messenger RNA changed what timelines mean in drug development. But speed only matters when it’s repeatable, inspection-ready, and scalable. Elise Biopharma is an in vitro mRNA synthesis CDMO engineered for exactly that: a single, digitally unified site where GMP plasmid DNA, high-yield IVT mRNA, robust dsRNA depletion, precision LNP formulation, and aseptic fill-finish operate under one quality system and one project team. From plasmid to patient-ready vial, we turn Design → Data → Decision into your competitive edge.

Why Elise for In Vitro mRNA Synthesis CDMO Programs

One site, one QMS. Plasmid → IVT → purification → LNP → fill-finish without cross-vendor ambiguity.
QbD that lives in production. We map QTPP → CQAs → CPPs, then drive them with inline/at-line PAT and electronic batch records (21 CFR Part 11, ALCOA+).
Analytics that close risk. Anti-dsRNA ELISA/dot-blot, intact-mass LC-MS, capillary electrophoresis, cap structure and poly(A) integrity, residuals, and potency readouts.
Scale on rails. Milligrams for research through multi-kilogram GMP mRNA and LNP—without changing the logic of the process.
Modality breadth. mRNA, saRNA, circular RNA, gRNA/crRNA, and combination payload regimens.
IVD support when relevant. ISO 13485 processes and design controls to align with diagnostics workflows when you need an IVD CDMO posture.

If you are searching for (ivt mrna synthesis services cdmo.), you’ll find the capability here—wrapped in a control strategy that reads like a regulator wrote it.

The Plasmid-to-LNP Continuum

GMP Plasmid DNA — Where Yield and Integrity Begin

Foundation strains. RNase-controlled, antibiotic-free E. coli; defined fed-batch to 2–4 g/L at 200–2,000 L scales.
Purity at process speed. Alkaline lysis + multi-step chromatography for ≥95% supercoiled; endotoxin ≤0.1 EU/mg typical.
Release & readiness. Restriction mapping, full sequence confirmation, supercoil ratio, residual HCP/DNA (qPCR), and DMF-ready documentation.
QbD hand-off. We link template topology to IVT yield and dsRNA risk in the CQA/CPP map you’ll keep using later.

High-Yield IVT mRNA

Reactors, 0.5–50 L single-use (100 L on request), jacketed temperature control, inline pH/Mg²⁺, and clean sampling.
Chemistry tuned to outcomes. High-processivity T7, CleanCap®/ARCA-compatible caps, NTP balance, Mg²⁺ titration to reduce abortives.
Results that matter. Up to 10 g finished mRNA per 50 L IVT; RIN ≥8.0, dsRNA <0.1% (typical), tight poly(A) control.
saRNA & circRNA. Replicon plasmids, DMOE-free IVT options, and circularization workflows with functional stability screens.

Purification & dsRNA Depletion

Enzymatic cleanup. DNase workflows and UF/DF (100 kDa) to remove enzymes, salts, and short species.
Chromatographic polish. Core-shell HPLC and anion-exchange tuned by DoE for dsRNA removal; orthogonal confirmation by ELISA/dot-blot.
Identity & structure. Intact-mass LC-MS for length confirmation; CE/bioanalyzer sizing; cap structure and poly(A) integrity.

LNP Formulation

Microfluidics that listen. Staggered-herringbone chips to 60–100 nm, PDI ≤0.05, encapsulation ≥95%. Real-time DLS drives FRR/TFR feedback to hold size ±3 nm.
Lipid library. Clinical ionizable lipids (e.g., MC3, SM-102, ALC-0315), helper lipids (DSPC, cholesterol, PEG-lipids), plus targeted custom chemistries.
Sterile by design. ISO 5 isolators, 0.22 µm final filters, closed connectors to fill-finish; residual ethanol monitored and controlled.

Aseptic Fill-Finish & Stability

Robotic isolators for vials/PFS at –20 °C to +8 °C, nitrogen overlay, low-shear flow paths.
Lyophilized LNP option using sucrose/trehalose matrices (program-specific feasibility).
ICH stability: real-time + accelerated with potency, size/PDI, encapsulation, sterility, endotoxin, and osmolality checkpoints.

Elise Biopharma, Biologics start faster with us

Digital Quality, QbD & PAT

QTPP → CQA → CPP as the Operating System

QTPP examples: route/dose, shelf life, target organ.
CQAs: cap 1 ratio, dsRNA content, size/PDI window, endotoxin, residuals/solvents.
CPPs: IVT temp, NTP/Mg²⁺ ratios, enzyme load, FRR/TFR set-points, post-mix aging.

PAT that Keeps You in Control

Inline pH/T°/Mg²⁺, at-line HPLC for NTP consumption, closed-loop DLS for particle size.
EBR + ALCOA+: electronic batch records (21 CFR Part 11), automated CoAs, exception-based review.

This is what you hire an in vitro mRNA synthesis CDMO for: fewer cycles to optimum, stronger batch-to-batch reproducibility, and cleaner inspections.

Onboarding in 30 Days

Technical dossier & risk register. Plasmid design, lipid preferences, dose/route, stability targets; draft risk map.
QbD alignment workshop. Agree QTPP/CQAs/CPPs; define success metrics (e.g., dsRNA threshold, cap ratio).
Chemistry & DoE plan. IVT DoE grid + dsRNA removal screens; pre-select lipid systems.
Analytics & methods. Method lifecycle plan (ICH Q2(R2)), refs/standards, preliminary acceptance criteria.
Project charter. Timeline, GxP boundary, deliverable calendar, QA/RA sign-off.

Deliverables: risk assessment, QbD/CPP map, draft control strategy, Gantt, and a sample plan that ties batch numbers to learning—not just output.

Engagement Tracks & Timelines

Track A — Template-to-Tox

Plasmid → IVT feasibility + dsRNA depletion → pilot LNP → 10–50 g non-GMP DS/DP with stability start.

Track B — Gene-to-IND

Full plasmid→IVT→purification→LNP→GMP lot release with QC, method qualification/validation as needed, and IND/IMPD CMC authoring support.

Track C — Commercial Ramp (PPQ & CPV)

Process performance qualification, continued process verification, dual-site transfer playbooks, and capacity planning (100M+ dose potential).

Extended Capabilities That Add Real Options

Molecular Biology CDMO Services (Template Enablement)

If you need molecular biology cdmo services upstream of IVT, our team covers:

Sequence design, codon optimization, 5′/3′ UTR engineering, and poly(A) length strategies aligned to your indication and dose route.
Cloning, high-copy/low-copy vector choices, promoter/ribo-switch options, and library construction for rapid screening.
Full sequence verification pipelines and release-ready template packages.

In Vitro Biology Services CDMO

Sponsors often need cell-based proof early. As an in vitro biology services cdmo, we run:

Transfection potency assays (primary cells and lines), reporter readouts, and expression kinetics.
Innate sensing panels (e.g., RIG-I/MDA5, TLRs) to balance dsRNA thresholds with immunogenicity goals.
In-vitro translation and functional protein assays for cytokine/enzymatic payloads.

These layers keep your in vitro mRNA synthesis CDMO program anchored in data that matters to clinicians and regulators.

IVD CDMO Alignment

When your mRNA is part of a diagnostic workflow (or you’re building RUO → IVD paths), we operate as an IVD CDMO:

ISO 13485 QMS, design controls, risk management (ISO 14971), verification/validation, and traceability.
Reagent and kit-building support: labeling, IFUs, shelf-life studies, and change-control governance compatible with IVD submissions.
Clean separation of therapeutic and diagnostic documentation so audits remain crisp.

mRNA Veterinary Vaccines (Animal Health Track)

For sponsors in animal health, we support mRNA veterinary vaccines with the same manufacturing discipline—plus species-aware considerations:

Dose/route tailoring (IM/SC/mucosal), LNP selection for tolerability, and adjuvant compatibility where appropriate.
Stability and cold-chain design tuned to field realities; packaging optimized for multi-dose vials in clinic settings.
Regulatory documentation aligned to regional animal-health frameworks; comparability plans for strain/payload updates.

Learn more about our Veterinary Biologics CDMO Services <–Here.

Capacity, Scheduling & Tech Transfer

Parallel lines for discovery (0.5–5 L), dev/GMP (5–50 L), and late-phase (50–100 L) IVT with matched purification/LNP suites.
Rapid slot activation using pre-qualified single-use kits and freeze-dried reagents; templated batch docs reduce QA cycle time.
Structured tech transfer: unit operations, CPPs, PAT models, and edge-case library so second sites can reproduce—not reinterpret—your process.
Supply chain with qualified primary/secondary sources for NTPs, cap analogs, enzymes, and clinical lipids; full BSE/TSE and origin docs.

Pricing Philosophy

We price by work-package and decision gate, not by endless hours:

Spend advances when evidence advances (e.g., dsRNA ≤ target, cap ratio within window, size/PDI in control).
Platform economics for multi-asset portfolios reuse methods and control strategies to drop marginal cost per program.
Transparent change control when new data justifies a different path.

Deliverables Checklist

Development

QbD map, DoE plans/results, PAT configuration, draft control strategy.
IVT batch records (dev), dsRNA profile, cap structure analysis.

GMP

Executed EBRs (Part 11), CoAs, full analytics, deviations/CAPA.
Stability protocols/reports, method qualification/validation packages.

Regulatory

IND/IMPD CMC modules, risk summary, comparability plan, PPQ/CPV outlines.

FAQ — In Vitro mRNA Synthesis CDMO Essentials

1) How fast can you go from plasmid to a non-GMP tox lot?

Our Template-to-Tox track typically delivers 10–50 g of non-GMP mRNA/LNP in ~4 months. The critical path is IVT yield optimization and dsRNA control, followed by LNP sizing and encapsulation efficiency that meets your CQA targets. We front-load DoE on NTP/Mg²⁺/enzyme ratios and cap analog selection, then lock FRR/TFR in microfluidics based on real-time DLS. If you bring a qualified plasmid template and prior IVT data, we can often accelerate by 3–6 weeks. Expect weekly technical reviews and a phase-gate before pilot lots are released for GLP tox.

2) What dsRNA level can you support—and how do you measure it?

Program-dependent, we routinely demonstrate <0.1% dsRNA by anti-dsRNA ELISA/dot-blot with orthogonal confirmation when warranted. We reduce dsRNA formation at the source (chemistry and temperature profile) and polish with anion-exchange / core-shell HPLC as needed. Release includes method suitability, controls, and trend charts so regulators can see batch-to-batch performance. If your target threshold is tighter, we’ll redesign unit ops around that CQA and show the trade-offs in yield, cost, and timelines.

3) Can you support saRNA and circular RNA at GMP?

Yes. For saRNA, we generate/qualify the replicon plasmid, tune IVT conditions for long transcripts, and validate an analytical stack appropriate for length and structure. For circRNA, we support template design and ligation workflows with identity/size verification by LC-MS and CE plus functional potency readouts. Each modality gets a risk register, revised CQAs (e.g., nicking/concatemers), and process-specific CPPs. GMP execution follows the same EBR/ALCOA+ discipline as conventional mRNA.

4) Do you provide aseptic fill-finish—and which containers?

Yes. We fill vials and prefilled syringes within ISO 5 isolators, with nitrogen overlay and low-shear pathways designed for fragile LNPs. Final 0.22 µm filtration, CCI testing, and visual inspection are standard for release. For programs sensitive to cold chain, we can evaluate lyophilized LNP with a sucrose/trehalose matrix, provided feasibility data justify it. We also run transport simulations to set label claims that reflect real shipping.

5) Can you help with diagnostics workflows as an IVD CDMO?

Absolutely. We operate an ISO 13485 branch for RUO→IVD reagent development, with design controls, risk management (ISO 14971), verification/validation, and traceability that aligns with IVD submissions. We separate therapeutic and diagnostic documentation so audits are crisp. If your program needs paired drug-diagnostic development, we coordinate the two schedules and share analytics where appropriate to reduce duplication.

6) Do you support animal health programs and mRNA veterinary vaccines?

Yes—on a dedicated path. We tailor dose/route (IM/SC/mucosal), LNP tolerability, packaging, and stability for species and field conditions. Regulatory posture covers USDA CVB for immunologicals and FDA CVM for therapeutics, with EU EMA/CVMP alignment where applicable. We also adapt potency/innate-sensing assays to species-relevant models to keep your data decision-useful.

7) What IVT and LNP scales do you run?

IVT reactors are 0.5–50 L single-use (100 L on request), paired with matched purification capacity and microfluidic formulation lines. LNP microfluidics deliver 60–100 nm particles with PDI ≤ 0.05 and encapsulation ≥ 95%. We design capacity in parallel lanes so research, development/GMP, and late-phase work can run concurrently. Scale decisions are driven by dose math, stability, and cost-per-dose targets—not just vessel availability.

8) How do you keep particle size and PDI consistent batch-to-batch?

We instrument the mixing step with closed-loop DLS and tie it to FRR/TFR set-points so the system corrects drift in real time. Post-mix aging is time/temperature-controlled; we reject size distributions that don’t stabilize inside your window. We also manage solvent removal and hold times to preserve encapsulation efficiency. Your release will include control charts for Z-avg, PDI, and EE%—data reviewers love those.

9) Can you absorb a process developed elsewhere (tech transfer)?

Yes. We’ll start with a TT dossier: unit ops, CPPs, equipment/consumables, edge-case library, and historical deviations/CAPA. We then run engineering lots to reproduce key CQAs before proposing improvements. Where incoming analytics are incomplete, we’ll fill gaps so a regulator can follow the thread from prior state to current. Our goal is equivalence first, optimization second—so your comparability argument is clean.

10) What’s the standard release testing panel for mRNA DS/DP?

Typical DS includes identity (intact-mass LC-MS), size/length (CE/bioanalyzer), cap structure, poly(A) integrity, dsRNA, residuals (template DNA, enzymes, solvents), endotoxin, and bioburden/sterility. DP adds size/PDI, encapsulation efficiency, osmolality, pH, visible/sub-visible particulates, and CCI. We tailor acceptance criteria to your QTPP (e.g., route, shelf life, dose) and provide method lifecycle plans (qualification→validation) aligned with phase.

11) How do you manage endotoxin and other residuals?

We push control upstream (RNase-controlled, antibiotic-free strains for plasmid; clean reagents; sanitary design) and verify downstream clearance with UF/DF and chromatography. Release includes LAL endotoxin, residual DNA/protein, solvents (e.g., ethanol), and enzyme carry-over. Trend charts and clearance rationales live in the batch record so inspectors can follow the logic. If your indication demands tighter limits, we’ll adapt the control strategy and show data to match.

12) What does QbD/PAT look like in practice (QTPP→CQA→CPP)?

We map QTPP (dose/route/shelf-life/organ targeting) to CQAs (e.g., cap-1 ratio, dsRNA %, size/PDI, endotoxin) and then to CPPs (IVT temperature, NTP/Mg²⁺ ratios, enzyme load, FRR/TFR). PAT provides inline/at-line signals—pH/temperature/Mg²⁺, NTP consumption by HPLC, DLS for LNP—so we can make real decisions during the batch. The result is fewer optimization cycles and stronger batch-release narratives. It’s the backbone of a modern in vitro mRNA synthesis CDMO.

13) How do you reduce dsRNA formation before polishing?

We tune IVT temperature/time profiles, NTP/Mg²⁺ balance, and polymerase load to minimize abortives. Template design (UTRs, poly(A) control) and cap chemistry also matter. When needed, we insert an AEX step with parameters discovered via DoE to pull dsRNA tails without punishing yield. The combined approach is how we routinely land <0.1% dsRNA with robust yields.

14) Which cap strategies do you support and how is capping verified?

We support co-transcriptional (e.g., CleanCap®/ARCA family) and post-transcriptional approaches when justified. Verification includes cap structure confirmation (enzymatic/LC-MS) and cap-1 ratio reporting appropriate to phase. We’ll show the trade-offs between cost, yield, and innate sensing for each strategy. Your CQA/CPP map will explicitly tie capping to potency and immunogenicity targets.

15) How do you control and verify poly(A) tail length?

We start with template design that encodes the desired poly(A) length and guard against slippage. Verification is by capillary electrophoresis and, where needed, LC-MS-based mapping. When your mechanism is sensitive to tail length, we’ll add routine checks to release and trend tails across stability. If “good enough” is fine for early phase, we’ll stage the burden appropriately to save time and money.

16) Do you offer lyophilized LNP—and what data do you need?

We do, after feasibility. We’ll propose cryo/lyo protectants (often sucrose/trehalose blends) and run a matrix of fill volume, cycle profiles, and reconstitution conditions. Success is measured by size/PDI, encapsulation, potency, and appearance before/after reconstitution. We then extend to accelerated/real-time stability to justify label claims for room-temperature or “refrigerated, do not freeze” storage.

17) How do you address innate immune sensing and immunogenicity?

We use in vitro biology services (our in vitro biology services cdmo layer) to screen RIG-I/MDA5/TLR responses and correlate dsRNA and cap metrics to cytokine readouts. For vaccines, some innate “spark” may be desirable; for protein replacement, it’s usually not. We’ll help you pick the balance and show how CQA control preserves it. Assay designs aim to be stable across phase so bridging is painless.

18) Can you run stability and shipping simulations end-to-end?

Yes. We run ICH real-time and accelerated stability, freeze-thaw cycles, agitation, and light exposure. For shipping, we simulate lane profiles (temperature spikes, vibration) and test after excursions. Reports include potency, size/PDI, encapsulation, appearance, sterility, endotoxin, and CCI where relevant. We’ll translate those data into practical shipping/handling instructions and proposed expiry dating.

19) What are realistic timelines for Gene-to-IND?

From final sequence and agreed QTPP, 9–12 months is typical for GMP DS/DP with full QC and CMC authoring support. The biggest schedule variables are method readiness, dsRNA targets, and fill-finish slotting. We operate in sprints (2–4 weeks) with evidence-based gates, so you always see cause→effect. If you bring prior data, we’ll use it to skip redundant work—after we verify it’s transferable.

20) How do you handle comparability and process changes?

We draft a comparability protocol early—targeting CQAs, analytics, and acceptance criteria—so improvements don’t derail timelines. Engineering runs bookend the change, and we use stats to argue “no clinically meaningful difference.” Documentation shows the chain of custody and data. Regulators generally reward this discipline because it makes their review easier.

21) How do you price projects—and can milestones be gated by evidence?

We quote by work-package (unit ops + analytics) with phase gates tied to CQAs (e.g., dsRNA threshold, cap ratio, size/PDI window). You pay when evidence advances. For portfolios, we apply platform economics to reuse methods and controls so marginal cost per asset drops. If you prefer fixed-fee with change-control, we can structure that too.

22) What’s your digital quality system and data integrity posture?

All manufacturing, PAT, and EM data flow into electronic batch records compliant with 21 CFR Part 11 and ALCOA+. We use exception-based review, automated CoAs, and audit trails that survive regulator scrutiny. Deviations/CAPA/change control are transparent and linked to batch history. This is how a modern in vitro mRNA synthesis CDMO keeps speed and quality aligned.

23) Do you offer upstream molecular biology cdmo services?

Yes. We design sequences (codon/GC/UTR/poly(A)), pick vectors/promoters, and build libraries for rapid screening. We also produce GMP plasmid templates with ≥95% supercoiled content and low endotoxin for clean IVT starts. The output is a template package with the documentation your IND/IMPD expects. Good templates make everything downstream easier.

24) Do you run potency and mechanism assays (in vitro biology services cdmo)?

We do. For mRNA, we run transfection potency, expression kinetics, and mechanism-linked functional assays. For LNPs, we profile uptake and intracellular delivery in relevant cells. Where innate sensing matters, we add RIG-I/MDA5/TLR panels and tie them to dsRNA/cap CQAs. Assays are staged (screening → qualified → validated) so burden matches phase.

25) Can you coordinate with antibody or protein programs (cross-modality)?

Yes. Many sponsors run mAbs or recombinant proteins in parallel with mRNA. We align analytics (identity/purity/potency) and share upstream/downstream know-how so your control strategies are consistent. Cross-modality governance saves time when programs converge (e.g., an mRNA priming vaccine paired with a therapeutic mAb). It also helps boards see portfolio-level risk reduced.

26) What supply-chain strategy do you use for critical reagents?

We qualify primary and secondary sources for NTPs, cap analogs, enzymes, and clinical lipids. Incoming materials get CoAs, genealogy, and risk classification; criticals sit under heightened control. For long programs, we propose safety stocks and requalification schedules. The aim is zero drama on the day you need to run.

27) Which geographies and regulators have you supported?

We work primarily under US/EU expectations (FDA/CBER/CVM, USDA CVB, EMA/CVMP) and support submissions to additional authorities via partners. Documents are written to be region-portable—users don’t want to rewrite CMC for every agency. If your plan includes multiple regions, we stage annexes and reference tables so reviewers can align faster.

28) How do you handle IP, confidentiality, and data access?

We execute robust CDAs/MSAs and restrict access on a need-to-know basis inside our QMS. You own your IP and data; we operate under defined background IP licenses where needed. We provide secure data rooms, version control, and immutable audit trails. At close-out, we deliver a data package organized the way regulators like to read it.

29) What cleanroom classifications and EM do you run?

Formulation/fill occurs in ISO 5 isolators within ISO 7/8 suites; upstream/downstream in ISO-classified rooms appropriate to phase. We run environmental monitoring (viable/non-viable particulates, surfaces, personnel) on GMP campaigns and trend the data. Deviations drive CAPA and are visible in batch records. You’ll receive EM summaries with every GMP lot.

30) How do we engage—and what should we bring to the kickoff?

Start with a 45-minute scoping call (objectives, dose/route, timelines, budget band). Bring any prior data (templates, IVT yields, dsRNA, LNP size, potency, stability) and your draft QTPP. Within five business days we return a program plan (unit ops, analytics, milestones, acceptance criteria) and a quote with phase gates. From there, onboarding (Day 0–30) covers risk mapping, DoE launch, PAT setup—and you’re moving.

How We Work With You

Scoping call (45 min): objectives, dose/route, timelines, budget band.
Data exchange: prior results, constraints, intended clinical path.
Draft program plan: timeline, unit ops, analytics, acceptance criteria.
Kickoff & 30-day onboarding: risk/QbD alignment, DoE launch, PAT config.
Operate in sprints: every 2–4 weeks, results → decisions → next set-points.
Phase gate: evidence clears GMP boundary; release methods and stability are in place pre-run.

The Elise mRNA Summary

Precision by default. Every set-point ties to a CQA.
Digital truth. EBRs, PAT, and CoAs make the argument for you.
Speed with guardrails. We accelerate by removing uncertainty, not steps.
Breadth without drift. From molecular biology cdmo services and in vitro biology services cdmo through LNP and fill-finish—under one roof.
Diagnostics & animal health ready. When you need an IVD CDMO stance or a path for mRNA veterinary vaccines, you won’t need a second vendor.

If your goal is a partner that behaves like a product company—fast, exacting, and inspection-ready—Elise Biopharma is the in vitro mRNA synthesis CDMO you want. Whether you need a focused feasibility sprint or a Gene-to-IND program with GMP lot release, we’ll return a QbD-anchored plan (timeline, unit ops, analytics, milestones) in five business days.

Elise Biopharma — In Vitro mRNA Synthesis CDMO
Plasmid-to-LNP Continuum │ Digital QC │ GMP Lot Release

Contact out team at info@elisebiopharma.com